0001402328 2026-01-01 2026-09-30 0001402328 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001402328 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001402328 2026-11-12 0001402328 2026-09-30 0001402328 2025-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001402328 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001402328 2026-07-01 2026-09-30 0001402328 2025-07-01 2025-09-30 0001402328 2025-01-01 2025-09-30 0001402328 2024-12-31 0001402328 2025-09-30 0001402328 us-gaap:CommonStockMember 2026-06-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001402328 us-gaap:PreferredStockMember 2026-06-30 0001402328 us-gaap:ComprehensiveIncomeMember 2026-06-30 0001402328 us-gaap:RetainedEarningsMember 2026-06-30 0001402328 2026-06-30 0001402328 us-gaap:CommonStockMember 2025-06-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001402328 us-gaap:PreferredStockMember 2025-06-30 0001402328 us-gaap:ComprehensiveIncomeMember 2025-06-30 0001402328 us-gaap:RetainedEarningsMember 2025-06-30 0001402328 2025-06-30 0001402328 us-gaap:CommonStockMember 2025-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001402328 us-gaap:PreferredStockMember 2025-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2025-12-31 0001402328 us-gaap:RetainedEarningsMember 2025-12-31 0001402328 us-gaap:CommonStockMember 2024-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001402328 us-gaap:PreferredStockMember 2024-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2024-12-31 0001402328 us-gaap:RetainedEarningsMember 2024-12-31 0001402328 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001402328 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2026-07-01 2026-09-30 0001402328 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001402328 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001402328 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2025-07-01 2025-09-30 0001402328 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001402328 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001402328 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2026-01-01 2026-09-30 0001402328 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001402328 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001402328 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2025-01-01 2025-09-30 0001402328 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001402328 us-gaap:CommonStockMember 2026-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001402328 us-gaap:PreferredStockMember 2026-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2026-09-30 0001402328 us-gaap:RetainedEarningsMember 2026-09-30 0001402328 us-gaap:CommonStockMember 2025-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001402328 us-gaap:PreferredStockMember 2025-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2025-09-30 0001402328 us-gaap:RetainedEarningsMember 2025-09-30 0001402328 2026-05-30 2026-06-01 0001402328 2026-10-25 2026-10-26 0001402328 2024-08-07 2024-08-08 0001402328 2024-04-16 2024-04-17 0001402328 2022-02-08 2022-02-09 0001402328 2020-01-01 2020-12-31 0001402328 2019-01-01 2019-12-31 0001402328 SBFM:NoraPharmaMember 2022-10-19 2022-10-20 0001402328 SBFM:MalekChamounMember SBFM:NoraPharmaMember 2022-10-20 0001402328 SBFM:MalekChamounMember 2026-01-01 2026-09-30 0001402328 2025-01-01 2025-12-31 0001402328 us-gaap:EquipmentMember 2026-09-30 0001402328 us-gaap:EquipmentMember 2025-12-31 0001402328 us-gaap:ComputerEquipmentMember 2026-09-30 0001402328 us-gaap:ComputerEquipmentMember 2025-12-31 0001402328 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001402328 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001402328 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001402328 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001402328 us-gaap:VehiclesMember 2026-09-30 0001402328 us-gaap:VehiclesMember 2025-12-31 0001402328 SBFM:AdvanomicsCorporationMember 2026-01-01 2026-09-30 0001402328 SBFM:AllDirectorsMember 2026-07-01 2026-09-30 0001402328 SBFM:AllDirectorsMember 2025-07-01 2025-09-30 0001402328 SBFM:AllDirectorsMember 2026-01-01 2026-09-30 0001402328 SBFM:AllDirectorsMember 2025-01-01 2025-09-30 0001402328 srt:DirectorMember 2026-04-30 0001402328 srt:DirectorMember 2026-04-01 2026-04-30 0001402328 srt:DirectorMember 2026-08-06 2026-08-07 0001402328 srt:DirectorMember 2026-08-01 2026-08-31 0001402328 srt:ChiefExecutiveOfficerMember us-gaap:SeriesBPreferredStockMember 2026-09-30 0001402328 srt:ChiefExecutiveOfficerMember us-gaap:SeriesBPreferredStockMember 2025-12-31 0001402328 SBFM:SeriesBWarrantExercisesMember us-gaap:CommonStockMember 2025-01-02 2025-01-03 0001402328 SBFM:SeriesBWarrantExercisesMember 2025-01-02 2025-01-03 0001402328 SBFM:SeriesBWarrantExercisesMember us-gaap:CommonStockMember 2025-04-01 2025-04-02 0001402328 SBFM:SeriesBWarrantExercisesMember 2025-04-01 2025-04-02 0001402328 us-gaap:CommonStockMember SBFM:RegisteredDirectOfferingMember 2025-04-01 2025-04-03 0001402328 SBFM:SeriesBWarrantExercisesMember us-gaap:CommonStockMember 2025-10-15 2025-10-16 0001402328 SBFM:SeriesBWarrantExercisesMember 2025-10-15 2025-10-16 0001402328 SBFM:PublicOffering2026Member 2026-05-18 2026-05-19 0001402328 SBFM:CommonUnitsMember SBFM:PublicOffering2026Member 2026-05-18 2026-05-19 0001402328 2026-07-19 2026-07-20 0001402328 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001402328 SBFM:TradeableWarrantsMember 2026-09-30 0001402328 SBFM:TradeableWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:PreFunded2022WarrantsMember 2026-09-30 0001402328 SBFM:PreFunded2022WarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:InvestorWarrantsMember 2026-09-30 0001402328 SBFM:InvestorWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:AprilWarrantsMember 2026-09-30 0001402328 SBFM:AprilWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:MayPreFundedWarrantsMember 2026-09-30 0001402328 SBFM:MayPreFundedWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:MayInvestorWarrantsMember 2026-09-30 0001402328 SBFM:MayInvestorWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:PreFunded2024WarrantsMember 2026-09-30 0001402328 SBFM:PreFunded2024WarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:SeriesAWarrantsMember 2026-09-30 0001402328 SBFM:SeriesAWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:SeriesBWarrantsMember 2026-09-30 0001402328 SBFM:SeriesBWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:PreFunded2025WarrantsMember 2026-09-30 0001402328 SBFM:PreFunded2025WarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:SeriesCWarrantsMember 2026-09-30 0001402328 SBFM:SeriesCWarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:PreFunded2026WarrantsMember 2026-09-30 0001402328 SBFM:PreFunded2026WarrantsMember 2026-01-01 2026-09-30 0001402328 SBFM:AprilWarrantsAndMayInvestorWarrantsMember 2024-02-10 2024-02-11 0001402328 SBFM:TradeableWarrantsMember 2022-02-17 2026-09-30 0001402328 SBFM:InvestorWarrantsMember 2022-02-17 2026-09-30 0001402328 SBFM:SeriesBWarrantsMember 2022-02-17 2026-09-30 0001402328 SBFM:SeriesCWarrantsMember 2022-02-17 2026-09-30 0001402328 2022-02-17 2026-09-30 0001402328 SBFM:TradeableWarrants1Member 2026-09-30 0001402328 SBFM:TradeableWarrants1Member 2026-01-01 2026-09-30 0001402328 SBFM:InvestorWarrants1Member 2026-09-30 0001402328 SBFM:InvestorWarrants1Member 2026-01-01 2026-09-30 0001402328 SBFM:SeriesBWarrants1Member 2026-09-30 0001402328 SBFM:SeriesBWarrants1Member 2026-01-01 2026-09-30 0001402328 SBFM:SeriesCWarrants1Member 2026-09-30 0001402328 SBFM:SeriesCWarrants1Member 2026-01-01 2026-09-30 0001402328 SBFM:SettlementAgreementMember 2026-07-07 2026-07-08 iso4217:USD shares iso4217:USD shares pure iso4217:CAD SBFM:Integer false --12-31 2026 Q3 0001402328

10-Q true 2026-09-30 false 001-41282 SUNSHINE BIOPHARMA INC. CO 20-5566275 333 Las Olas Way CU4 Suite 433 Fort Lauderdale FL 33301 954 330-0684 Common Stock Common Stock Purchase Warrants SBFM SBFMW NASDAQ NASDAQ Yes Yes Non-accelerated Filer true false false 823772

14618614

9123308

3891806

3459864

11662251

13472025

422880

408839

798384

31004390

26853581

361916

557370

1893448

1889370

599203

778846

2854567

3225586

33858957

30079167

4325878

5664212

295797

268276

200138

215637

4794292

6443922

427427

596785

427427

596785

5221719

7040707

0.10

1000000

130000

13000

0.001

3000000000

278317

24530

278

108310889

98105870

-639946

-65309

-79046983

-75015126

28637238

23038460

33858957

30079167

9442325

9417179

26794777

27728750

6340623

6343639

19085403

18501918

3101702

3073540

7709374

9226832

170369

135413

510979

504783

646948

159003

1108960

1261017

100000

300000

388519

193009

808598

285203

198535

235217

658095

835236

818595

614661

2452390

2347144

1563

119298

46509

530807

1856341

1833172

5488485

5407294

136715

119909

404863

342760

554650

1616459

74609

95821

229442

233147

4392194

4160153

12008321

13663850

-1290492

-1086613

-4298947

-4437018

-25676

-10250

-25676

-10250

-48160

253

-48184

2644

76850

75352

174092

223434

103320

3014

65355

203552

215828

-1287478

-1021258

-4095395

-4221190

-63538

-137438

-63538

-386765

-1223940

-883820

-4031857

-3834425

18989

-601628

-574637

509118

-1204951

-1485448

-4606494

-3325307

-5.20

-38.80

-26.43

-195.37

235308

22780

152539

19626

-4031857

-3834425

229442

233147

-25676

1616459

169192

606402

157466

-1352092

2410073

422880

-0

-362421

-291716

-153183

-147016

-1151894

375084

-157256

-129741

-295797

152874

-4374080

-3715409

185956

620817

-44759 175530

56921

10250

-84276

-786097

7316895

1828596

2719185

2195312

10036080

4023908

9123308

9686529

5577724

-477598

-82418

97507

14618614

9306438

119426

119

106006861

130000

13000

-658935

-77823043

27538002

2915

72289

72292

93174

2231802

2231895

62802

63 -63 0 0 0 0

18989

-1223940

-1204951

278317

278

108310889

130000

13000

-639946

-79046983

28637238

22780

97381373

130000

13000

280787

-71990379

25684804

-601628

-883820

-1485448

22780

97381373

130000

13000

-320841

-72874199

24199356

24530

98105870

130000

13000

-65309

-75015126

23038460

13066 13 808022 808035 19112 19 1911131 1911150

60000

5084940

5085000

3415

169189

169192

93174

2231802

2231895

65020

65 -65 0 0 0 0

-574637

-4031857

-4606494

278317

278

108310889

130000

13000

-639946

-79046983

28637238

12901

93357474

130000

13000

-829959

-69039774

23500754

3937 4 2195308 2195312

5942

1828591

1828597

509118

-3834425

-3325307

22780

97381373

130000

13000

-320841

-72874199

24199356

<p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z2ea2NafRSwc" style="font: 10pt Arial, sans-serif; margin: 0pt 0; text-align: justify; color: #00487F">Note 1 – Description of Business The Company was incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition, the Company changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical company. Sunshine Biopharma has two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation with a portfolio of pharmaceutical products consisting of 61 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation which develops and sells nonprescription, over-the-counter (“OTC”) supplements. The Company operates the two subsidiaries as a single business segment. Sales of the OTC supplements represent less than 3% of the Company’s total annual sales. The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, Provincial governments in Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement programs, making generic drugs prices highly dependent on government policies which may change over time. The most recent negotiations between the pan-Canadian Pharmaceutical Alliance (“pCPA”), the entity that negotiates drug prices on behalf of the government, and the Canadian Generic Pharmaceutical Association (“CGPA”) resulted in updated generic pricing for certain products which took effect on October 1, 2023 (the “2023 Generic Drug Pricing Agreement”). The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On June 11, 2026, the pCPA and CGPA announced an agreement to exercise the extension option and extended the 2023 Generic Drug Pricing Agreement for an additional two years, effective October 1, 2026. On February 10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare Act. These developments further strengthened the Canadian generic drug market. In addition, the Company is engaged in the development of the following proprietary drugs: <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">·</td> <td style="text-align: justify">K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections</td></tr> </table>

Note 2 – Basis of Presentation The unaudited financial statements of the Company for the three and nine month periods ended September 30, 2026 and 2025 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2025, was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026. These financial statements should be read in conjunction with that report.

Note 3 – Reverse Stock Splits Effective June 1, 2026 and October 26, 2026, the Company completed a 1-for-10 and a 1-for-20 reverse split of its common stock, respectively. The Company had previously completed five (5) reverse stock splits including a 1-for-20 on August 8, 2024, a 1-for-100 on April 17, 2024, a 1-for-200 on February 9, 2022, and two 1-for-20 reverse splits, one in 2020 and the other in 2019. The Company’s financial statements included in this report reflect all seven (7) reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

1-for-10

1-for-20

1-for-100

1-for-200

1-for-20

Note 4 – Acquisition of Nora Pharma Inc. On October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (“Nora Pharma”), a Canadian privately held pharmaceutical company. The purchase price for the shares was $18,860,637 which was paid in cash ($14,346,637) and by the issuance of 10 shares of the Company’s common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zdc5jwSZjMeb" title="Stock issued for acquisition, value">4,514,000 or $451,400.00 per share. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma’s operations are authorized by a Drug Establishment License issued by Health Canada. As part of the consideration for Nora Pharma, the Company agreed to a $<span id="xdx_903_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zHzsDg3NfSl8" title="Earnout payable">5,000,000 CAD ($<span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zHQJtpAfmIT7" title="Earnout payable">3,632,000 USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout was payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the purchase agreement for the acquisition) above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company would not be terminated pursuant to the Company’s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During the fiscal year ended December 31, 2023, the Company paid an earnout amount of $1,426,914 CAD (approximately $1,036,500 USD) for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid another earnout amount of $3,093,878 CAD (approximately $2,247,400 USD) for the fiscal year ended December 31, 2023. The remaining earnout amount of $479,208 CAD ($295,797 USD) was paid by the Company to Mr. Chamoun on August 10, 2026 following the settlement of an employment related dispute between the Company and Mr. Chamoun reached on July 8, 2026 (See Note 15).

18860637

14346637

4514000

5000000 3632000 During the fiscal year ended December 31, 2023, the Company paid an earnout amount of $1,426,914 CAD (approximately $1,036,500 USD) for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid another earnout amount of $3,093,878 CAD (approximately $2,247,400 USD) for the fiscal year ended December 31, 2023. The remaining earnout amount of $479,208 CAD ($295,797 USD) was paid by the Company to Mr. Chamoun on August 10, 2026

Note 5 – Intangible Assets Intangible assets consisted of the following: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWFhA5DhPVf4" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of intangible assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Intangible assets at beginning of period, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260930_z1hWYOFQGcBk" style="width: 13%; text-align: right" title="Intangible assets at beginning of period">1,889,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_z5Qie7UhLgfc" style="width: 13%; text-align: right" title="Intangible assets at beginning of period">3,019,717</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Purchase of additional intangible assets</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20260101__20260930_zDCcGw0k3Lh7" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">124,441</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231_zdGHnFX0BQD" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">774,355</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260930_zZoCUqYvsi4" style="text-align: right" title="Intangible assets at ending of period">2,013,811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zWLNCEUqgxM" style="text-align: right" title="Intangible assets at ending of period">3,794,072</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less impairment*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260930_fKg_____zPnlq5zYsOX6" style="text-align: right" title="Less impairment">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20250101__20251231_fKg_____zTXv7wBhMGX2" style="text-align: right" title="Less impairment">(1,748,247</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated amortization</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260930_zkIsr7pRfGc3" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(120,363</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zbKDd3LNMDW6" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(156,455</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">Intangible assets, net</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260930_zv635Z8oVrx" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,893,448</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zxEf1iM9QZaf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,889,370</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 13px">*</td> <td style="text-align: justify">The impairment was a result of determination by the Company that certain product licenses could not be commercialized.</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWFhA5DhPVf4" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of intangible assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Intangible assets at beginning of period, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260930_z1hWYOFQGcBk" style="width: 13%; text-align: right" title="Intangible assets at beginning of period">1,889,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_z5Qie7UhLgfc" style="width: 13%; text-align: right" title="Intangible assets at beginning of period">3,019,717</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Purchase of additional intangible assets</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20260101__20260930_zDCcGw0k3Lh7" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">124,441</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20250101__20251231_zdGHnFX0BQD" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">774,355</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260930_zZoCUqYvsi4" style="text-align: right" title="Intangible assets at ending of period">2,013,811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zWLNCEUqgxM" style="text-align: right" title="Intangible assets at ending of period">3,794,072</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less impairment*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260930_fKg_____zPnlq5zYsOX6" style="text-align: right" title="Less impairment">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20250101__20251231_fKg_____zTXv7wBhMGX2" style="text-align: right" title="Less impairment">(1,748,247</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated amortization</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260930_zkIsr7pRfGc3" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(120,363</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zbKDd3LNMDW6" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(156,455</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">Intangible assets, net</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260930_zv635Z8oVrx" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,893,448</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zxEf1iM9QZaf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,889,370</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 13px">*</td> <td style="text-align: justify">The impairment was a result of determination by the Company that certain product licenses could not be commercialized.</td></tr> </table>

1889370

3019717

124441

774355

2013811

3794072

-1748247

120363

156455

1893448

1889370

Note 6 – Plant, Property and Equipment Property, plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following: <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zolEFzeNOQf2" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of property, plant and equipment</td><td> </td> <td colspan="2" id="xdx_499_20260930_zxq1rRpNjhAi" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20251231_z6hoP0yyXsUe" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUUJLbPyinwk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">291,434</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">335,464</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zgV6oc96RPgb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69,139</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zuPHMIFHUTy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,462</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zNCSYCVfqw3l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92,706</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z8KxxjjbU1B6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Vehicles</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">407,579</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">507,478</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_z3pV1pHRsR27" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">927,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,249</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zKKZKGG0lH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated depreciation</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(565,201</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(512,879</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_z2lIjlcYkyFk" style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">Plant, property and equipment, net</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">361,916</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">557,370</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zolEFzeNOQf2" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of property, plant and equipment</td><td> </td> <td colspan="2" id="xdx_499_20260930_zxq1rRpNjhAi" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20251231_z6hoP0yyXsUe" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUUJLbPyinwk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">291,434</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">335,464</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zgV6oc96RPgb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69,139</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zuPHMIFHUTy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,462</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zNCSYCVfqw3l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92,706</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z8KxxjjbU1B6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Vehicles</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">407,579</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">507,478</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_z3pV1pHRsR27" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">927,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,249</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zKKZKGG0lH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated depreciation</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(565,201</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(512,879</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_z2lIjlcYkyFk" style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">Plant, property and equipment, net</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">361,916</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">557,370</td><td style="border-bottom: Black 2.5pt double; text-align: left"> </td></tr> </table>

291434

335464

90292

69139

43850

45462

93961

92706

407579

507478

927117

1070249

565201

512879

361916

557370

Note 7 – Inventory Inventory consists solely of finished goods purchased for resale. Inventory is stated at cost which represents the amount paid to acquire the finished goods. The Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical sell-through patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company records an allowance for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently reversed. Inventory is comprised of the following: <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zueunmrkzHF4" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of inventory</td> <td> </td> <td colspan="2" id="xdx_49F_20260930_zb9lW0o3YSS" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_495_20251231_z4vBf8DshJS7" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Period Ended</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2026</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2025</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zC43Rp0fAO7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Inventory (finished goods)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">12,475,986</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">13,947,178</td> <td style="width: 1%"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryValuationReserves_iNI_di_z0CFPA9MPNni" style="vertical-align: bottom; background-color: White"> <td style="border-bottom: black 1pt solid">Allowance for obsolete inventory</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(813,735</td> <td style="border-bottom: black 1pt solid">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(475,797</td> <td style="border-bottom: black 1pt solid">)</td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iI_zTeKkF1QHNqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: black 2.25pt double">Inventory, net of allowance</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">11,662,251</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">13,472,025</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zueunmrkzHF4" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of inventory</td> <td> </td> <td colspan="2" id="xdx_49F_20260930_zb9lW0o3YSS" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_495_20251231_z4vBf8DshJS7" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Period Ended</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2026</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2025</td> <td style="border-bottom: black 1pt solid"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zC43Rp0fAO7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Inventory (finished goods)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">12,475,986</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">13,947,178</td> <td style="width: 1%"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryValuationReserves_iNI_di_z0CFPA9MPNni" style="vertical-align: bottom; background-color: White"> <td style="border-bottom: black 1pt solid">Allowance for obsolete inventory</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(813,735</td> <td style="border-bottom: black 1pt solid">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(475,797</td> <td style="border-bottom: black 1pt solid">)</td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iI_zTeKkF1QHNqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: black 2.25pt double">Inventory, net of allowance</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">11,662,251</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">13,472,025</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

12475986

13947178

813735

475797

11662251

13472025

Note 8 – Leases The Company has obligations as a lessee for warehouse and office space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company’s lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease include fixed payments plus a variable payment. The Company’s office space lease requires it to make variable payments for the Company’s proportionate share of the building’s property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when incurred. Amounts reported on the balance sheet as of September 30, 2026 were as follows: <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zllxBWhFcRil" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)"> <tr style="vertical-align: bottom"> <td> Schedule of lease information</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 83%">Operating lease ROU asset</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260930_zehDWI86IKgc" style="width: 13%; text-align: right" title="Operating lease ROU asset">599,203</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating Lease liability - Short-term</td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260930_zhxemjq0vgn2" style="text-align: right" title="Operating Lease liability - Short-term">200,138</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating lease liability - Long-term</td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260930_zkO9sZUIYR14" style="text-align: right" title="Operating lease liability - Long-term">427,427</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Remaining lease term</td> <td> </td> <td> </td> <td style="text-align: right">3 Years 3 Months</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Discount rate</td> <td> </td> <td> </td> <td style="text-align: right">6%</td> <td> </td></tr> </table> Amounts disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying amount of ROU assets resulting from deferred rent. Maturities of lease liabilities under non-cancellable operating leases at September 30, 2026 are as follows: <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zuj3eGbPeUoi" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease liabilities)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of maturities of lease liabilities</td><td> </td> <td colspan="2" id="xdx_495_20260930_zjmDb8xfHj27" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zR0BfV3B42y5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">51,055</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zidVYMeZaBLk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">197,483</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zUEczKJj5jW" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">187,210</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_z8a76SY84l97" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">177,464</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zkuxK0vRetp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Thereafter</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14,353</td><td style="text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zllxBWhFcRil" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)"> <tr style="vertical-align: bottom"> <td> Schedule of lease information</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 83%">Operating lease ROU asset</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260930_zehDWI86IKgc" style="width: 13%; text-align: right" title="Operating lease ROU asset">599,203</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating Lease liability - Short-term</td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260930_zhxemjq0vgn2" style="text-align: right" title="Operating Lease liability - Short-term">200,138</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating lease liability - Long-term</td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260930_zkO9sZUIYR14" style="text-align: right" title="Operating lease liability - Long-term">427,427</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Remaining lease term</td> <td> </td> <td> </td> <td style="text-align: right">3 Years 3 Months</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Discount rate</td> <td> </td> <td> </td> <td style="text-align: right">6%</td> <td> </td></tr> </table>

599203

200138

427427

3 Years 3 Months

0.06

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zuj3eGbPeUoi" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease liabilities)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of maturities of lease liabilities</td><td> </td> <td colspan="2" id="xdx_495_20260930_zjmDb8xfHj27" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zR0BfV3B42y5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">51,055</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zidVYMeZaBLk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">197,483</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zUEczKJj5jW" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">187,210</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_z8a76SY84l97" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">177,464</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zkuxK0vRetp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Thereafter</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14,353</td><td style="text-align: left"> </td></tr> </table>

51055

197483

187210

177464

14353

Note 9 – Income Taxes Our income tax benefits as stated reflect tax benefits recorded by Nora Pharma, the Company’s wholly owned Canadian subsidiary. Deferred tax benefits generated in the United States and Canada are offset by valuation allowances by jurisdiction. The Company maintains a full valuation allowance against its deferred tax assets because of cumulative losses and insufficient positive evidence of future taxable income. Deferred tax assets are regularly reviewed for recoverability by jurisdiction and valuation allowances are established based on historical and projected future taxable income or losses and the expected timing of reversals of existing temporary differences. The Company has recorded valuation allowances against all of its deferred tax assets of September 30, 2026, and the Company expects to maintain these valuation allowances until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time. The Company operates through two Canadian subsidiaries that are subject to Canadian federal and provincial income taxes. The Company recognizes a tax benefit from an uncertain tax position only when it is more likely than not that the position will be sustained upon examination, based on its technical merits. The amount recognized is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company has not recognized any material uncertain tax benefits in its financial statements. On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the United States. Among other provisions, the OBBBA made permanent 100% bonus depreciation and domestic research-cost expensing and amended the rules under Sections 951A and 250 for taxable years beginning after December 31, 2025. The Company completed its assessment of the provisions applicable to its operations. The OBBBA did not have a material effect on the Company's income tax expense for the three and nine months ended September 30, 2026, primarily because the Company maintains a full valuation allowance against its net deferred tax assets and had no current-period Section 951A inclusion.

Note 10 – Management and Director Compensation The Company paid its officers aggregate cash compensation of $433,460 and $788,322 for the three-month periods ended September 30, 2026 and 2025, respectively. For the nine-month periods ended September 30, 2026 and 2025, the Company paid its officers aggregate cash compensation of $1,420,801 and $2,316,641, respectively. Of the amounts paid through September 30, 2026, $<span id="xdx_904_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zPyiRt5KRC2b" title="Officers compensation">472,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company. The Company paid its directors aggregate cash compensation of $100,000 for each of the three-month periods ended September 30, 2026 and 2025, and $300,000 for each of the nine-month periods ended September 30, 2026 and 2025. In April 2026, one of the directors of the Company received a stock award of 500 shares of common stock valued at $96,900. In August 2026, the same director received another stock award of 2,915 shares of common stock valued at $71,709.

433460

788322

1420801

2316641

472000

100000

300000

500

96900

2915

71709

Note 11 – Capital Stock The Company’s authorized capital is comprised of 3,000,000,000 shares of common stock, par value $0.001, and 30,000,000 shares of preferred stock, $0.10 par value. As of September 30, 2026, the Company had authorized 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock is non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to the common stock and gives the holder the right to 1,000 votes per share. As of September 30, 2026, <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zztCNzWK0dNb" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zbmbIQyqrzff" title="Preferred stock, shares outstanding">130,000 shares of Series B Preferred Stock were outstanding and held by the Company’s Chief Executive Officer. On January 3, 2025, the Company issued <span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zqLRViARErIf" title="Stock converted, shares issued">638 shares of common stock upon the exercise of <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember_zBdMUGHuMhDj" title="Stock converted, shares converted">638 Series B Warrants and received $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember_zow5LGWHkYr6" title="Proceeds from warrant exercise">355,298 in net proceeds. On April 2, 2025, the Company issued <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zeVhdvdaltae" title="Stock converted, shares issued">3,300 shares of common stock upon the exercise of <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember_zGcjTx29Cc4" title="Stock converted, shares converted">3,300 Series B Warrants and received $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember_zLaWfaLlMfZ1" title="Proceeds from warrant exercise">1,840,014 in net proceeds. On April 3, 2025, the Company issued an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_ziquvJtke0Bf" title="Stock issued new, shares">5,942 shares of common stock in connection with a registered direct offering and received $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zdaGW3u1jJRa" title="Proceeds from issuance of common stock">1,828,596 in net proceeds. On October 16, 2025, the Company issued <span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJchBsPinMha" title="Stock converted, shares issued">1,750 shares of common stock upon the exercise of <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember_zZASvwskDTwd" title="Stock converted, shares converted">1,750 Series B Warrants and received net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20251015__20251016__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBWarrantExercisesMember_zMCTfkaoXO8j" title="Proceeds from warrant exercise">724,500. On April 14, 2026, the Company issued 500 shares of common stock to one of its directors for services rendered to the Company. On May 19, 2026, the Company completed a public offering and received gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20260518__20260519__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOffering2026Member_zBltsH3ss1k1" title="Proceeds from sale of equity">6.0 million. The offering consisted of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260518__20260519__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOffering2026Member__us-gaap--StatementClassOfStockAxis__custom--CommonUnitsMember_ztIbfyzfUcvb" title="Stock issued new, shares">60,000 Common Units (or Pre-Funded Units), <span id="xdx_90A_ecustom--UnitDescription_c20260518__20260519__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOffering2026Member__us-gaap--StatementClassOfStockAxis__custom--CommonUnitsMember_zrQIqW0Ufn3a" title="Description of Units">each consisting of (i) one (1) share of common stock or one (1) pre-funded warrant and (ii) two (2) Series C Warrants to purchase one (1) share of common stock per warrant at an initial exercise price of $100.00. The public offering price per Common Unit was $100.00 (or $99.998 per Pre-Funded Unit, which is equal to the public offering price per Common Unit sold in the offering minus an exercise price of $0.002 per share under the pre-funded warrants). The pre-funded warrants were immediately exercisable and could be exercised at any time until exercised in full. All of the pre-funded warrants have been exercised as of September 30, 2026. The Series C Warrants are exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series C Warrants are subject to adjustment as described in more detail in the final prospectus filed in connection with the offering. On July 20, 2026, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Aegis Capital Corp. (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock, for an aggregate offering price of up to $4,000,000, in “at-the-market” offerings through or to the Agent, as exclusive sales agent (the “ATM Offering”). Subject to the terms and conditions of the Sales Agreement and the applicable placement notice, sales of the Company’s common stock may be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Company’s common stock. The Agent will receive a commission from the Company of 3.0% of the gross proceeds from the sale of any shares of common stock under the Sales Agreement, in addition to reimbursement of certain expenses. Through September 30, 2026, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesOther_c20260701__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zA3u3HinvOGg" title="Common stock issued through ATM offering, shares">93,174 shares of its common stock under the ATM Offering and received $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueOther_c20260701__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zhsgQizNSGXd" title="Common stock issued through ATM offering">2,231,895 in net proceeds. On August 7, 2026, the Company issued 2,915 shares of common stock to one of its directors for services rendered to the Company. As of September 30, 2026 and December 31, 2025, the Company had 278,317 and 24,530 shares of common stock issued and outstanding, respectively. The Company has declared no dividends since inception.

3000000000

0.001

30000000

0.10

1000000

130000

638

355298

3300

1840014

5942

1828596

1750

724500

500

6000000

60000

each consisting of (i) one (1) share of common stock or one (1) pre-funded warrant and (ii) two (2) Series C Warrants to purchase one (1) share of common stock per warrant at an initial exercise price of $100.00. On July 20, 2026, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Aegis Capital Corp. (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock, for an aggregate offering price of up to $4,000,000, in “at-the-market” offerings through or to the Agent, as exclusive sales agent (the “ATM Offering”). Subject to the terms and conditions of the Sales Agreement and the applicable placement notice, sales of the Company’s common stock may be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Company’s common stock. The Agent will receive a commission from the Company of 3.0% of the gross proceeds from the sale of any shares of common stock under the Sales Agreement, in addition to reimbursement of certain expenses.

93174

2231895

2915

278317

24530

Note 12 – Warrants The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. In 2022, 2023, 2024, 2025, and 2026, the Company completed seven (7) financing events, and in connection therewith, it issued warrants as follows: <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zAPqSM6WEvT" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Schedule of warrants issued with financing</td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="border-bottom: Black 1pt solid"> </td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="border-bottom: Black 1pt solid"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Issuance Date/Type</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: justify">Feb 17, 2022 (“Tradeable Warrants”)*</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_fKg_____z852ybvK9D6e" style="width: 13%; text-align: right" title="Warrants outstanding">11</td><td style="width: 2%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_fKg_____zDHGjCxfak1d" style="font-size: 9pt">888,000.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 15%; text-align: justify">February 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Mar 14, 2022 (“2022 Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2022WarrantsMember_zsFc3Hh76gak" style="text-align: right" title="Warrants outstanding">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">200.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Mar 14, 2022 (“Investor Warrants”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">888,000.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">March 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Apr 28, 2022 (“April Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilWarrantsMember_zb78ui6j8Apl" style="text-align: right" title="Warrants outstanding">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,504,000.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">April 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">May 16, 2023 (“May Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayPreFundedWarrantsMember_zCatEz0dXgpc" style="text-align: right" title="Warrants outstanding">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">400.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">May 16, 2023 (“May Investor Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayInvestorWarrantsMember_zNwByiFipwR4" style="text-align: right" title="Warrants outstanding">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">236,000.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">November 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Feb 15, 2024 (“2024 Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2024WarrantsMember_znoxgyYf9wb2" style="text-align: right" title="Warrants outstanding">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">400.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Feb 15, 2024 (“Series A Warrants”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left">**</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">840,000</td><td style="text-align: left">**</td><td> </td> <td style="text-align: justify">August 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Feb 15, 2024 (“Series B Warrants”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left">**</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">952,000.00</td><td style="text-align: left">**</td><td> </td> <td style="text-align: justify">February 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Apr 3, 2025 (“2025 Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2025WarrantsMember_zwnfy6wiSbU5" style="text-align: right" title="Warrants outstanding">1,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">May 19, 2026 (“Series C Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_fKio___zJrjh2DzsJF7" style="text-align: right" title="Warrants outstanding">120,000</td><td style="text-align: left">**</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100.00</td><td style="text-align: left">**</td><td> </td> <td style="text-align: justify">May 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: justify">May 19, 2026 (“2026 Pre-Funded Warrants”)</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2026WarrantsMember_zhvjr8n437eh" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding">4,200</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.002</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: justify">Unlimited</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">*</td> <td style="text-align: justify; width: 97%">These warrants trade on Nasdaq under the symbol SBFMW.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">**</td> <td style="text-align: justify">Subject to adjustment.</td></tr> </table> On February 11, 2024, the Company redeemed all of the April Warrants and all of the May Investor Warrants for an aggregate purchase price of $<span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zUHOhOQuNv5h" title="Payments for repurchase of warrants">3,139,651. The Series A Warrants, which had been exercised in full, expired on August 15, 2026. As of September 30, 2026, all of the pre-funded warrants, a total of 157 Tradeable Warrants, 141 Investor Warrants, 86,937 Series B Warrants (as adjusted), and 382,230 Series C Warrants were exercised resulting in aggregate net proceeds of $20,856,176 received by the Company. The Company’s outstanding warrants as of September 30, 2026 consisted of the following: <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVvn6Arl208a" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Schedule of warrants outstanding </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: justify">Type</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: justify">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; text-align: justify">Tradeable Warrants</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrants1Member_zy1hwxKUkmUb" style="width: 13%; text-align: right" title="Number of warrants outstanding">3</td> <td style="width: 2%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrants1Member_zEh8fYXM2Pkh" style="width: 13%; text-align: right" title="Warrant exercise price">44,000.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 15%; text-align: justify"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrants1Member_zqFIsTlQ51aa" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">February 2027</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Investor Warrants</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrants1Member_ztqblgi9ZE8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrants1Member_zj7i9uItAL7d" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">800,000.00</td> <td> </td> <td> </td> <td style="text-align: justify"><span id="xdx_900_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrants1Member_ziDDyAWb80Zg" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">March 2027</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Series B Warrants</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrants1Member_fKg_____z2mOur3QlVca" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,290,354</td> <td>*</td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrants1Member_fKg_____zr1AR1Wtiade" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">24.092</td> <td>*</td> <td> </td> <td style="text-align: justify"><span id="xdx_907_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrants1Member_zslBEpuYXB85" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">February 2029</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid; text-align: justify">Series C Warrants</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrants1Member_zjIXkj8KAaB5" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">201,777</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrants1Member_zGrJtQHY6lE3" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">50.00</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: justify"><span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrants1Member_zLdRYalUAEc7" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 2031</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">*</td> <td style="text-align: justify; width: 97%">The Series B Warrants adjusted to 11,233,359 warrants exercisable at $2.7674 following the 1-for-20 reverse split completed by the Company on October 26, 2026.</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zAPqSM6WEvT" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Schedule of warrants issued with financing</td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="border-bottom: Black 1pt solid"> </td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="border-bottom: Black 1pt solid"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Issuance Date/Type</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: justify">Feb 17, 2022 (“Tradeable Warrants”)*</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_fKg_____z852ybvK9D6e" style="width: 13%; text-align: right" title="Warrants outstanding">11</td><td style="width: 2%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_fKg_____zDHGjCxfak1d" style="font-size: 9pt">888,000.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 15%; text-align: justify">February 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Mar 14, 2022 (“2022 Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2022WarrantsMember_zsFc3Hh76gak" style="text-align: right" title="Warrants outstanding">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">200.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Mar 14, 2022 (“Investor Warrants”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">888,000.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">March 2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Apr 28, 2022 (“April Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilWarrantsMember_zb78ui6j8Apl" style="text-align: right" title="Warrants outstanding">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,504,000.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">April 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">May 16, 2023 (“May Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayPreFundedWarrantsMember_zCatEz0dXgpc" style="text-align: right" title="Warrants outstanding">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">400.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">May 16, 2023 (“May Investor Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayInvestorWarrantsMember_zNwByiFipwR4" style="text-align: right" title="Warrants outstanding">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">236,000.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">November 2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Feb 15, 2024 (“2024 Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2024WarrantsMember_znoxgyYf9wb2" style="text-align: right" title="Warrants outstanding">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">400.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Feb 15, 2024 (“Series A Warrants”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left">**</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">840,000</td><td style="text-align: left">**</td><td> </td> <td style="text-align: justify">August 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Feb 15, 2024 (“Series B Warrants”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left">**</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">952,000.00</td><td style="text-align: left">**</td><td> </td> <td style="text-align: justify">February 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Apr 3, 2025 (“2025 Pre-Funded Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2025WarrantsMember_zwnfy6wiSbU5" style="text-align: right" title="Warrants outstanding">1,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Unlimited</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">May 19, 2026 (“Series C Warrants”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_fKio___zJrjh2DzsJF7" style="text-align: right" title="Warrants outstanding">120,000</td><td style="text-align: left">**</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100.00</td><td style="text-align: left">**</td><td> </td> <td style="text-align: justify">May 2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: justify">May 19, 2026 (“2026 Pre-Funded Warrants”)</td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFunded2026WarrantsMember_zhvjr8n437eh" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding">4,200</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.002</td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: justify">Unlimited</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">*</td> <td style="text-align: justify; width: 97%">These warrants trade on Nasdaq under the symbol SBFMW.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">**</td> <td style="text-align: justify">Subject to adjustment.</td></tr> </table>

888000.00

February 2027

200.00

Unlimited

888000.00

March 2027

1504000.00

April 2027

400.00

Unlimited

236000.00

November 2028

113

400.00

Unlimited

840000

August 2026

952000.00

February 2029

1300

0.20

Unlimited

120000

100.00

May 2031

4200

0.002

Unlimited

3139651

2026-08-15 157 141 86937 382230

20856176

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVvn6Arl208a" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Schedule of warrants outstanding </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: justify">Type</td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: justify">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; text-align: justify">Tradeable Warrants</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrants1Member_zy1hwxKUkmUb" style="width: 13%; text-align: right" title="Number of warrants outstanding">3</td> <td style="width: 2%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrants1Member_zEh8fYXM2Pkh" style="width: 13%; text-align: right" title="Warrant exercise price">44,000.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 15%; text-align: justify"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrants1Member_zqFIsTlQ51aa" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">February 2027</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Investor Warrants</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrants1Member_ztqblgi9ZE8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrants1Member_zj7i9uItAL7d" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">800,000.00</td> <td> </td> <td> </td> <td style="text-align: justify"><span id="xdx_900_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrants1Member_ziDDyAWb80Zg" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">March 2027</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Series B Warrants</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrants1Member_fKg_____z2mOur3QlVca" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,290,354</td> <td>*</td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrants1Member_fKg_____zr1AR1Wtiade" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">24.092</td> <td>*</td> <td> </td> <td style="text-align: justify"><span id="xdx_907_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrants1Member_zslBEpuYXB85" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">February 2029</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid; text-align: justify">Series C Warrants</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrants1Member_zjIXkj8KAaB5" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">201,777</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrants1Member_zGrJtQHY6lE3" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">50.00</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: justify"><span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrants1Member_zLdRYalUAEc7" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 2031</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">*</td> <td style="text-align: justify; width: 97%">The Series B Warrants adjusted to 11,233,359 warrants exercisable at $2.7674 following the 1-for-20 reverse split completed by the Company on October 26, 2026.</td></tr> </table>

44000.00

February 2027

800000.00

March 2027

1290354

24.092

February 2029

201777

50.00

May 2031

Note 13 – Earnings Per Share The following table sets forth the computation of basic* net (loss) per share: <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zjDcOGzBOEg1" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Schedule of basic net loss per share</td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="border-bottom: Black 1pt solid"> </td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Nine Months Ended September 30,</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Net gain (loss) attributable to common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,031,857</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,834,425</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,539</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,626</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: justify">Net gain (loss) per share attributable to common stock</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26.43</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(195.37</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%">*</td> <td style="text-align: justify; width: 97%">Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zjDcOGzBOEg1" style="font: 10pt Arial, sans-serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Schedule of basic net loss per share</td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="border-bottom: Black 1pt solid"> </td><td style="border-bottom: Black 1pt solid"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Nine Months Ended September 30,</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Net gain (loss) attributable to common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,031,857</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,834,425</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average outstanding shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,539</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,626</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: justify">Net gain (loss) per share attributable to common stock</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26.43</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(195.37</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%">*</td> <td style="text-align: justify; width: 97%">Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.</td></tr> </table>

-4031857

-3834425

152539

19626

-26.43

-195.37

Note 14 – Segment Reporting The Company operates as one operating segment, which is also its one reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (“CODM”), evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company’s operations are managed as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and supplements. Although the Company conducts activities through multiple legal entities — including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc. (Canada) — these entities operate under a unified management structure with shared economic characteristics, common product development objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under ASC 280 – Segment Reporting. In accordance with ASU 2023-07, the Company provides the following information regarding its single reportable segment: <table cellpadding="0" cellspacing="0" style="font: 10pt Arial, sans-serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">Measure of Segment Profit (Loss): The CODM evaluates performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated financial statements.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Significant Segment Expenses: Research and development expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed on a consolidated basis.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Other Segment Items: Interest income, interest expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Reconciliation: As the Company has only one reportable segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.</td></tr> </table> The Company’s operations are conducted in Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.

Note 15 – Legal Matters On April 10, 2025, the Company terminated the employment of Mr. Malek Chamoun, president of the Company’s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the Company received a demand letter from the attorneys of Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately $5,300,000 USD) within five (5) days. On July 8, 2026, the Company entered into an agreement of transaction and mutual release (the “Settlement Agreement”) with Mr. Chamoun. Pursuant to the Settlement Agreement, the Company agreed to pay Mr. Chamoun $1,500,000 CAD (approximately $1,060,000 USD) in full and final settlement of the dispute between the parties. The total amount of the settlement had been accrued under earnout payable, salaries, and reimbursable employee expenses. The Company paid this amount in accordance with the Settlement Agreement on August 10, 2026.

1500000

1060000

Note 16 – Subsequent Events On October 9, 2026, the Company completed a public offering and received gross proceeds of approximately $6.0 million. The offering consisted of (A) 525,455 common units (the “Common Units”), each consisting of (i) one share of the Company’s common stock, and (ii) two series D warrants (the “Series D Warrants”), each exercisable for one share of common stock; and (B) 20,000 pre-funded units (the “Pre-Funded Units”), each consisting of (i) one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of common stock and (ii) two Series D Warrants. The purchase price of each Common Unit was $11.00, and the purchase price of each Pre-Funded Unit was $10.9998. The Pre-Funded Warrants have an exercise price of $0.0002 were exercised in full upon the closing of the Offering. The Series D Warrants are exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series D Warrants are subject to adjustment as described in more detail in the final prospectus filed in connection with the offering. On October 9, 2026, the Company received notice of a claim filed with the American Arbitration Association by the attorneys of Mr. Andrew Telsey, the Company’s former legal counsel, asserting that the Company owes Mr. Telsey unpaid compensation under an agreement for legal services dated January 1, 2023 and an unsigned consulting agreement dated November 1, 2024. The Company believes this claim is without merit and intends to defend its position vigorously. On October 26, 2026, the Company completed a 1-for-20 reverse split of its common stock. On November 2, 2026, the Company's Series B Warrants were adjusted to 11,233,359 warrants with an exercise price of $2.7674 per share as a result of the reverse split of the Company's common stock completed on October 26, 2026.

false false false false The impairment was a result of determination by the Company that certain product licenses could not be commercialized. These warrants trade on Nasdaq under the symbol SBFMW. Subject to adjustment. The Series B Warrants adjusted to 11,233,359 warrants exercisable at $2.7674 following the 1-for-20 reverse split completed by the Company on October 26, 2026. Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.